Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2151319 | 1.00 | FOLH1 (0.57) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Hydrochloric Acid SCHEMBL28514579 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Water SCHEMBL28303756 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Hydrochloric Acid SCHEMBL29268898 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Hydrochloric Acid SCHEMBL3647090 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Ammonia Solution, Strong SCHEMBL4951257 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| SCHEMBL31739266 | 0.94 | FOLH1 (0.50) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| SCHEMBL20448161 | 0.94 | FOLH1 (0.50) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Hydrochloric Acid SCHEMBL20482193 | 0.92 | FOLH1 (0.49) | FOLH1GSRSLC6A5RNPEPTLR2 | |
| Ammonia Solution, Strong SCHEMBL4951217 | 0.92 | FOLH1 (0.49) | FOLH1GSRSLC6A5RNPEPTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925300-A | IL 12 mRNA lipid nanoparticle and preparation method and application thereof | 杭州宜生医药科技发展有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119770369-A | Lipopeptide-small molecule polypeptide supermolecule composition and preparation method and application thereof | 江南大学 | 2025-04-08 | — | — | CN | claimed |
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337261-A2 | COMPOSITIONS AND METHODS FOR MODULATING MRNA SPLICING | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337676-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| CN-117561271-A | Cyclic cell penetrating peptides | 恩特拉达治疗公司 | 2024-02-13 | — | — | CN | claimed |
| CN-106727672-A | It is a kind of to treat medicine of vascular headache and preparation method thereof | 河南八灵电子科技有限公司 | 2017-05-31 | — | — | CN | claimed |
| EP-2706360-A1 | Methods for improving diabetes management | PreventAge Healthcare, LLC (US) | 2014-03-12 | — | — | EP | claimed |
| US-20130345175-A1 | Methods for Improving Diabetes Management | PREVENTAGE HEALTHCARE, LLC | 2013-12-26 | — | — | US | claimed |
| US-20060281687-A1 | Cyclin groove inhibitors | CYCLACEL LIMITED (GB) | 2006-12-14 | — | — | US | claimed |
| CN-1822824-A | Methods of treating degenerative disc disease | DEPUY SPINE INC (US) | 2006-08-23 | — | — | CN | claimed |
| US-6811965-B2 | REPERFUSION SOLUTION FOR USE IN THE PRESERVATION OF ORGAN TISSUE | HERMACELL PERFUSION, INC. | 2004-11-02 | — | — | US | claimed |
| US-20030104348-A1 | Kidney perfusion solution containing nitric oxide donor | HERMACELL PERFUSION, INC. | 2003-06-05 | — | — | US | claimed |
| CN-1096855-C | Composition for treating and inducing nitric oxide synthase expression and application thereof | MEDINOX INC (US) | 2002-12-25 | — | — | CN | claimed |
| WO-2001065935-A1 | KIDNEY PERFUSION SOLUTION CONTAINING NITRIC OXIDE DONOR | VODOVOTZ YORAM (US) | 2001-09-13 | — | — | WO | claimed |
| CN-1202824-A | Combinational therapeutic methods employing nitric oxide scavengers | MEDINOX INC (US) | 1998-12-23 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281687-A1 | Cyclin groove inhibitors | CCNC, CCNH, CCNI | FOLH1 1572/4885GSR 2058/4885SLC6A5 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.